Innovative Cancer Treatments Tosk specializes in developing drugs that mitigate the adverse effects of existing cancer therapies, opening opportunities to collaborate with hospitals, oncology clinics, and pharmaceutical companies seeking to improve patient outcomes and treatment tolerability.

Strong Research Backing With ongoing support from a $2 million NCI grant and recent clinical successes, Tosk demonstrates a promising pipeline that could attract partnerships for co-development, licensing, or procurement of its innovative therapies.

Expanding Expert Network The addition of top-tier scientific and medical advisors signals a commitment to advancing their pipeline, which can present opportunities for CROs, research institutions, and medical device firms to engage in collaborative research or advisory roles.

Early-Stage Revenue Potential Having completed Phase 2 trials and launched the flagship drug TK-90, Tosk is positioned for near-term commercialization, creating potential sales channels with oncology centers and specialty pharmacies seeking novel supportive care options.

Niche Market Focus Tosk’s focus on targeting KRAS-driven cancers and side effect prevention addresses significant unmet needs in oncology, making it an attractive partner for biopharma firms aiming to expand in targeted cancer therapeutics and supportive care markets.